Clinical and comparative utility of afatinib in non-small cell lung cancer

Código QR

Clinical and comparative utility of afatinib in non-small cell lung cancer

Manolo D'Arcangelo, Fred R HirschUniversity of Colorado Denver, Department of Medical Oncology, Aurora, CO, USAAbstract: The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	D'Arcangelo M, Hirsch FR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/460cf2b06c744ca9bf19605f969c0e31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
por: D&#39;Arcangelo M, et al.
Publicado: (2013)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
por: Gang Chen, et al.
Publicado: (2013)

Clinical use of crizotinib for the treatment of non-small cell lung cancer
por: Roberts PJ
Publicado: (2013)

Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Ziyu Wang, et al.
Publicado: (2021)

Detection of micrometastases in peripheral blood of non-small cell lung cancer with a refined immunomagnetic nanoparticle enrichment assay
por: Li Q, et al.
Publicado: (2011)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
por: William Boland, et al.
Publicado: (2010)

Phenotypic Changes of LncRNA Hotair in Non-Small-Cell Lung Cancer and Its Clinical Application
por: Haihua Huang, et al.
Publicado: (2021)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Vamsidhar Velcheti, et al.
Publicado: (2010)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà T
Publicado: (2017)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Chad A Reade, et al.
Publicado: (2009)

Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer
por: Ying-Qiang Lu, et al.
Publicado: (2017)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Jaclyn Flanigan, et al.
Publicado: (2010)

Cetuximab and biomarkers in non-small-cell lung carcinoma
por: Patil N, et al.
Publicado: (2012)

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
por: Diao WY, et al.
Publicado: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report
por: Lander Van Acker, et al.
Publicado: (2021)

Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer
por: Guo LG, et al.
Publicado: (2012)

Functional promoter rs189037 variant of ATM is associated with decrease in lung diffusing capacity after irradiation for non–small-cell lung cancer
por: Jose Luis Lopez Guerra, et al.
Publicado: (2018)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kyoichi Kaira, et al.
Publicado: (2021)

Delivery of curcumin by directed self-assembled micelles enhances therapeutic treatment of non-small-cell lung cancer [Corrigendum]
por: Zhu WT, et al.
Publicado: (2017)

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
por: Gupta N, et al.
Publicado: (2013)

GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation
por: Cheng L, et al.
Publicado: (2014)

Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer
por: Song X, et al.
Publicado: (2017)

Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis
por: Chuan-Yong Mu, et al.
Publicado: (2015)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012)

Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda M, et al.
Publicado: (2015)

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
por: Rui Wan, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model
por: Peng L, et al.
Publicado: (2014)

Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies
por: Thierry Berghmans, et al.
Publicado: (2021)

Application of Multifunctional Targeting Epirubicin Liposomes in the Treatment of Non-Small-Cell Lung Cancer [Corrigendum]
por: Song X, et al.
Publicado: (2021)

Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy
por: Xia Y, et al.
Publicado: (2018)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Diego Kauffmann-Guerrero, et al.
Publicado: (2021)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Sara Bravaccini, et al.
Publicado: (2021)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan MMK, et al.
Publicado: (2015)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
por: M. Yoon, et al.
Publicado: (2016)